# Bolt Biotherapeutics, Inc.: overview BOLT · Nasdaq · CIK 1641281 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bolt.md) · [Financials](/companies/bolt/financials.md) · [Filings](/companies/bolt/filings.md) · [Insiders](/companies/bolt/insiders.md) Latest reported revenue: [$5.0k](/filings/0001193125-26-344597.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-344597). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.1](/filings/0001193125-25-277549.md) | [0.0 d](/filings/0001193125-26-104121.md) | [1.2](/filings/0001193125-26-219382.md) | [1.8](/filings/0001193125-26-344597.md) | [2.2](/filings/0001193125-25-277549.md) | [2.5 d](/filings/0001193125-26-104121.md) | [0.0](/filings/0001193125-26-219382.md) | [0.0](/filings/0001193125-26-344597.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1441.1%)](/filings/0001193125-25-277549.md) | not reported | [(991.4%)](/filings/0001193125-26-219382.md) | [(510.5%)](/filings/0001193125-26-344597.md) | [(355.1%)](/filings/0001193125-25-277549.md) | [(283.4%) d](/filings/0001193125-26-104121.md) | [(29234.6%)](/filings/0001193125-26-219382.md) | [(167480.0%)](/filings/0001193125-26-344597.md) | | Net margin | % | [(1330.1%)](/filings/0001193125-25-277549.md) | not reported | [(903.4%)](/filings/0001193125-26-219382.md) | [(474.6%)](/filings/0001193125-26-344597.md) | [(329.4%)](/filings/0001193125-25-277549.md) | [(265.2%) d](/filings/0001193125-26-104121.md) | [(27861.5%)](/filings/0001193125-26-219382.md) | [(154400.0%)](/filings/0001193125-26-344597.md) | | Diluted EPS | $ per share | [(7.93)](/filings/0001193125-25-277549.md) | not reported | [(5.76)](/filings/0001193125-26-219382.md) | [(4.46)](/filings/0001193125-26-344597.md) | [(3.72)](/filings/0001193125-25-277549.md) | not reported | [(4.31)](/filings/0001193125-26-219382.md) | [(4.57)](/filings/0001193125-26-344597.md) | | Free cash flow | $m | [(14.0) d](/filings/0001193125-25-277549.md) | [(14.4) d](/filings/0001193125-26-104121.md) | not reported | not reported | [(9.8) d](/filings/0001193125-25-277549.md) | [(7.2) d](/filings/0001193125-26-104121.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.3](/filings/0000950170-23-010613.md) | [5.7](/filings/0000950170-24-034692.md) | [7.9](/filings/0000950170-25-043873.md) | [7.7](/filings/0001193125-26-104121.md) | [7.7](/filings/0001193125-26-104121.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(7364.1%)](/filings/0000950170-23-010613.md) | [(1576.6%)](/filings/0000950170-24-034692.md) | [(967.4%)](/filings/0000950170-25-043873.md) | [(949.9%)](/filings/0001193125-26-104121.md) | [(469.3%)](/filings/0001193125-26-104121.md) | | Net margin | % | [(7824.7%)](/filings/0000950170-23-010613.md) | [(1537.8%)](/filings/0000950170-24-034692.md) | [(878.6%)](/filings/0000950170-25-043873.md) | [(820.8%)](/filings/0001193125-26-104121.md) | [(433.7%)](/filings/0001193125-26-104121.md) | | Diluted EPS | $ per share | [(2.97)](/filings/0000950170-23-010613.md) | [(2.36)](/filings/0000950170-24-034692.md) | [(1.83)](/filings/0000950170-25-043873.md) | [(33.06)](/filings/0001193125-26-104121.md) | [(17.85)](/filings/0001193125-26-104121.md) | | Free cash flow | $m | [(59.4)](/filings/0000950170-23-010613.md) | [(78.5)](/filings/0000950170-24-034692.md) | [(69.7)](/filings/0000950170-25-043873.md) | [(61.3)](/filings/0001193125-26-104121.md) | [(39.9)](/filings/0001193125-26-104121.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bolt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Sofinnova Investments, Inc.](/funds/1631134.md) | 2026-06-30 | $530.2k | 137,721 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $379.7k | 98,625 | | Added +21,400 | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $278.8k | 72,414 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $219.1k | 56,903 | | Added +46,794 | | [T3 Companies, LLC](/funds/2052441.md) | 2026-06-30 | $146.3k | 38,000 | | Unchanged | | [Board of Trustees of The Leland Stanford Junior University](/funds/1315828.md) | 2026-06-30 | $138.5k | 35,977 | | Unchanged | | [Pfizer Inc](/funds/78003.md) | 2026-06-30 | $133.8k | 31,305 | | Unchanged | | [Lynx1 Capital Management LP](/funds/1910456.md) | 2026-06-30 | $118.6k | 30,800 | | Unchanged | | [NANO CAP NEW MILLENNIUM GROWTH FUND L P](/funds/1277890.md) | 2026-06-30 | $105.9k | 27,500 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $73.6k | 19,119 | | Reduced −9,672 | ## Recent filings [All 293 filings](/companies/bolt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 10:31 ET | [8-K](/filings/0001193125-26-429647.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-429647 | | 2026-10-06 | 16:07 ET | [8-K](/filings/0001193125-26-415560.md) | 1.01 Entry into a material agreement | 0001193125-26-415560 | | 2026-08-11 | 16:06 ET | [10-Q](/filings/0001193125-26-344597.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344597 | | 2026-08-11 | 16:05 ET | [8-K](/filings/0001193125-26-344580.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344580 | | 2026-06-11 | 16:05 ET | [8-K](/filings/0001193125-26-267487.md) | 5.07 Shareholder vote results | 0001193125-26-267487 | | 2026-05-12 | 16:06 ET | [10-Q](/filings/0001193125-26-219382.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219382 | | 2026-05-12 | 16:05 ET | [8-K](/filings/0001193125-26-219361.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219361 | | 2026-04-28 | 16:05 ET | [DEF 14A](/filings/0001193125-26-186923.md) | Proxy statement, period 2026-04-27 | 0001193125-26-186923 | | 2026-03-12 | 16:07 ET | [10-K](/filings/0001193125-26-104121.md) | Annual report, period 2025-12-31 | 0001193125-26-104121 | | 2026-03-12 | 16:05 ET | [8-K](/filings/0001193125-26-104102.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-104102 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-104121.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ab41c567-f130-4722-aecf-a778ea92d597) ## About the filer - CIK: 1641281 - Tickers: BOLT - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:22 ET. No prices; not investment advice.